In a clinical trial in pediatric patients aged 12 years with normal baseline heart rate, more patients treated with Wegovy injection compared to placebo had maximum changes in heart rate of 20 bpm or more (54% vs 39%)
The barrier will still be an investigational new drug application in an FDA designated disease indication (of which for many of these peptide use cases, there isn't one)
Besides burping, Wegovy has a range of side effects
Biotransformation is mainly done through what is called the phase I and phase II pathways in the liver
While information is limited, tirzepatide and other GLP-1 agonists have been reported to cause suicidal thoughts, inflammation of the pancreas, low blood sugar, and gall bladder problems
Association between the use of antihyperglycemic drugs and dementia risk: a case-control study